CHICAGO, Ill., May 26, 2026
Emalex Biosciences announced that Phase 3 clinical data for ecopipam, its investigational dopamine-1 (D1) receptor antagonist, were published in JAMA Neurology, showing significant benefits in delaying relapse and maintaining tic reduction in patients with Tourette syndrome. The publication marks an important milestone for the company as ecopipam represents a first-in-class therapy targeting the dopamine D1 receptor pathway, a mechanism distinct from currently approved Tourette treatments that primarily act on D2 receptors.
Phase 3 Trial Demonstrates Significant Tic Control Benefits
The randomized withdrawal Phase 3 study evaluated ecopipam in both pediatric and adult patients with Tourette syndrome and demonstrated that the investigational therapy significantly delayed time to relapse compared with placebo while maintaining clinically meaningful reductions in tic severity for up to 24 weeks. The study achieved statistical significance in both the pediatric subgroup and the combined overall population.
According to the published findings, ecopipam reduced the risk of relapse by approximately 50% in pediatric participants (HR = 0.5, P = 0.0084) and in the combined pediatric and adult population (HR = 0.5, P = 0.0050). Researchers reported that patients receiving ecopipam maintained durable improvement in motor and vocal tic symptoms during long-term treatment.
The study was authored by Donald L. Gilbert, MD, MS, of Cincinnati Children’s Hospital Medical Center, along with collaborators, and was registered under ClinicalTrials.gov identifier NCT05615220. The publication in JAMA Neurology significantly increases scientific visibility for ecopipam as a potential new therapeutic option in a disease area with limited innovation.
Advertisement
First-in-Class D1 Receptor Antagonist Targets New Pathway
Ecopipam is a first-in-class investigational compound designed to block dopamine signaling at the D1 receptor, which researchers believe may play a critical role in the repetitive and compulsive behaviors associated with Tourette syndrome. Current FDA-approved therapies for Tourette syndrome primarily target D2 dopamine receptors, often leading to side effects including weight gain, metabolic complications, and movement disorders.
The Phase 3 data showed that ecopipam was generally well tolerated, with the most commonly reported adverse events including somnolence (11.1%), anxiety (9.7%), headache (9.7%), insomnia (8.8%), tic worsening (7.9%), and fatigue (6.5%). Importantly, investigators reported no clinically meaningful effects on body weight, metabolic parameters, or drug-induced movement disorders, factors that could differentiate ecopipam from currently available therapies.
Because of its novel mechanism and unmet medical need in pediatric Tourette syndrome, ecopipam has already received both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA). The therapy remains investigational and has not yet received regulatory approval.
Tourette Syndrome Market Sees Growing Innovation Interest
Tourette syndrome is a chronic neurodevelopmental disorder characterized by involuntary motor and vocal tics that can significantly impair social functioning, emotional well-being, education, and quality of life. Despite available therapies, many patients continue to experience inadequate symptom control or struggle with side effects linked to dopamine-blocking treatments.
Emalex Biosciences, founded by Paragon Biosciences, is focused on developing new treatments for central nervous system disorders with limited therapeutic options. The company is positioning ecopipam as a differentiated therapy that could potentially redefine treatment standards for Tourette syndrome by targeting the dopamine D1 receptor pathway rather than traditional D2 pathways.
In addition to clinical development, ecopipam is currently available in the United States through an Expanded Access Program for eligible patients with Tourette syndrome who have exhausted approved treatment options. Access is granted outside formal clinical trials following physician request and institutional review board approval.
The newly published Phase 3 data strengthen the growing momentum behind ecopipam and could support future regulatory discussions as Emalex advances development of its first-in-class CNS therapy.
Source: Emalex Biosciences press release
